JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB264671

Human ZMYM3 knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

ZMYM3 KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 2 bp deletion in exon 2. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
1 Images
Sanger Sequencing - Human ZMYM3 knockout HeLa cell line (AB264671)
  • Sanger seq

Unknown

Sanger Sequencing - Human ZMYM3 knockout HeLa cell line (AB264671)

Homozygous : 2 bp deletion in exon 2.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 2 bp deletion in exon 2

Disease

Adenocarcinoma

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab264671-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255448 Human wild-type HeLa cell line", "number":"AB264671-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab264671 Human ZMYM3 knockout HeLa cell line", "number":"AB264671-CMP01" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab264671-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab264671 Human ZMYM3 knockout HeLa cell line", "number":"AB264671-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255448 Human wild-type HeLa cell line", "number":"AB264671-CMP02" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab264671-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab264671 Human ZMYM3 knockout HeLa cell line", "number":"AB264671-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab264671-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab264671 Human ZMYM3 knockout HeLa cell line", "number":"AB264671-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
ZMYM3
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

ZMYM3 also known as Zinc Finger MYM-Type Containing 3 is a protein with a molecular mass of about 155 kDa. It acts as a transcriptional regulator by binding to specific DNA sequences through its zinc-finger domains. ZMYM3 is mainly expressed in the brain and testes suggesting its role in neural and reproductive functions. The protein localizes primarily in the nucleus where it interacts with chromatin to modulate the expression of target genes.
Biological function summary

There are multiple roles of ZMYM3 in cellular processes. It is part of the CoREST complex a multiprotein scaffold involved in transcriptional repression. Through its participation in this complex ZMYM3 contributes to chromatin remodeling and epigenetic silencing of genes playing a role in maintaining the balance of gene expression necessary for normal cellular operations and development.

Pathways

There are several ways ZMYM3 impacts cellular communication and regulation. The protein is involved in the Notch signaling pathway which is important for cell differentiation proliferation and apoptotic processes. ZMYM3 influences this pathway alongside related proteins such as CoREST and LSD1. Additionally it interacts within the androgen receptor signaling pathway potentially impacting gene transcription relevant to sexual development and hormone response.

There is significant interest in the connection between ZMYM3 and cognitive impairments including X-linked intellectual disability. Mutations or dysregulation in ZMYM3 can lead to disrupted transcriptional control linking the protein to neurological disorders. Another medical condition linked to ZMYM3 is prostate cancer where it may affect androgen receptor pathways thereby implicating interactions with proteins like LSD1 and the androgen receptor itself in the disease's progression.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com